Andover, MA and Littleton, MA – Royal Philips (NYSE: PHG, AEX: PHIA), a leader in image-guided therapies, today announced that it has signed an agreement with Image Stream Medical (ISM) that allows Philips to further expand its integration solutions for its hybrid suite and interventional lab solutions with integrated video and live streaming capabilities. As part of the agreement, Philips has acquired a minority stake in ISM. Financial terms of the agreement were not disclosed.

The trend towards image-guided minimally invasive therapies continues to grow, requiring integrated solutions that enable physicians to optimally perform their procedures. ISM is a leading provider of advanced solutions for the control, routing, capturing and management of data and images utilized in various procedural environments, including hybrid suites and interventional labs. Through this partnership, Philips will be able to offer complete integration solutions and associated consultancy services, complementing its offering of live-image guided solutions, clinical informatics and services. The combined Philips and ISM offering will be available in the US from January 2015 onwards.

“Integrated video and live streaming capabilities have become increasingly critical to connecting clinicians and enabling remote collaboration, in both interventional and hybrid environments,” said Bert van Meurs, General Manager Image-Guided Therapy at Philips. “With a similar consultative approach to customer engagements, the partnership with Image Stream Medical is a natural extension of our current image-guided minimal invasive therapy offering, and this addition further reinforces our commitment to connecting care across the health continuum.”

Image-guided minimally invasive therapies, particularly those performed in the hybrid suite, are complex and technically demanding. They however provide key benefits for health systems and patients, including reduced patient trauma, shorter recovery times and shorter hospital stays, thereby contributing to lower health care costs. For these procedures there is a clear need for the comprehensive integration of real-time information from all relevant technologies, thus making these procedures more effective and easier to perform.

With this collaboration Philips will be able to extend its successful portfolio in the interventional and hybrid domain with comprehensive integration of real-time information in and outside the lab.
For the past 15 years, ISM’s platform, including audio/video integration, informatics integration, recording, streaming and conferencing solutions, has enabled more effective collaborative environments for conducting minimally invasive surgical procedures. EasySuiteTM, ISM’s latest integrated solution is designed to enhance operating room, hybrid suite and interventional lab flexibility, staff satisfaction, patient safety and enables secure and easy sharing and archiving of data inside and outside the lab – including data for the Electronic Medical Record (EMR).

“Image Stream Medical is very pleased to enter into this partnership with Philips in the image-guided therapy field, a natural extension of our perioperative solution.” said Eddie Mitchell, CEO of Image Stream Medical. “ISM provides a workflow centered platform for integrating surgical and procedural video information across the hospital enterprise, facilitating efficiency, teamwork, collaboration and learning. The complexity of the hybrid suite demands these capabilities. By partnering with Philips, ISM solutions will bring value not only to Philips’ hybrid suite customers, but also to its interventional lab customers.”

Philips’ focus on image-guided therapies is a strategic component of the company’s holistic approach to the delivery of care across the health continuum, from healthy living and prevention, to diagnosis, treatment, recovery and home care. Philips and ISM will showcase their combined solutions at booth #6742 at the Radiological Society of North America Annual Meeting (RSNA), November 30th through December 5th in Chicago, Ill. Visit www.philips.com/rsna and follow @PhilipsHealth for more information on Philips’ presence at #RSNA14.

AND

Philips debuts new radiology solutions at 2014 Radiology Society of North America Annual Meeting
Radiation dose management, informatics and image-guided solutions showcase future of radiology

Andover, MA – In a major exhibition at the 2014 Radiological Society of North America Annual Meeting (RSNA), Royal Philips (NYSE: PHG, AEX: PHIA) today revealed a full range of radiology solutions. Visitors to the Philips booth (#6742) will experience Philips’ breadth of diagnostic imaging, informatics and image-guided therapy solutions designed to increase clinical performance while creating a superior patient experience and driving cost-effective and high-quality care for health systems.
One of the leading global conferences on radiology care, RSNA 2014 will showcase the industry’s most promising research and leading innovations. At 12 noon CT on November 30th, Royal Philips CEO Frans van Houten will officially open the Philips booth, highlighting radiology’s role in driving the future of health technology, and introducing the launch of two new solutions in the area of dose management and informatics.
“Radiology is and will always be at the heart of the health continuum, as it is central to diagnosis and ensuring the right treatment reaches patients at the right time,” said van Houten. “In an increasingly connected world, Philips is committed to working with our customers to create innovative solutions that seamlessly integrate imaging technology with data analytics, consulting and services, to deliver more effective and lower cost health solutions.”

Radiology’s role in disease management is becoming increasingly important, and the ability to identify disease in its earliest stages, as well as assess response to therapeutic intervention, is critical. Philips will showcase its full range of advanced radiology technologies and solutions at RSNA enabling early, confident diagnosis that can help lead to effective treatment and restore healthy living, with a focus on:

Driving Clinical Performance
• Vereos PET/CT – World’s first and only true digital PET/CT offers approximately twice the volumetric resolution, sensitivity gain and quantitative accuracy compared to analog systems.
• IQon Spectral CT – Industry-first CT that adds spectral resolution to the image quality, delivering both anatomical information and the ability to characterize structures based on material content.
• EPIQ Ultrasound – Philips’ most powerful architecture ever applied to ultrasound imaging delivers more clinical information, with highly detailed images, extraordinary temporal resolution and superb tissue uniformity, even on technically challenging patients.
• Affiniti Ultrasound*– Innovative ultrasound system designed to help radiology departments deliver high quality patient care while facing increased patient loads with fewer resources.
• IntelliSpace PACS – Expedites results to referring physicians and enables efficient collaboration with other clinicians to make more informed decisions and improve patient care.
• Oncology Dashboard – Disease follow-up data is captured in a single, patient-centric overview to facilitate communication and next steps between oncologists and radiologists.

Enhancing Patient Experience
• Ingenia 1.5T S with Ambient MR In-Bore – Offers a soothing audiovisual experience to relax patients while inside an MRI scanner.
• MicroDose SI – Comfortable and less stressful mammography experience maintains outstanding image quality using non-invasive spectral applications.
• AlluraClarity Interventional Suites – Industry-leading interventional X-ray systems to guide minimally invasive procedures offering high image quality at a low X-ray dose for neurology, oncology and cardiology.

Delivering Improved Economic Value
• Diagnostic X-Ray Suite – DuraDiagnost, DigitalDiagnost, MobileDiagnost and ProGrade comprise a suite of flexible digital radiography solutions designed to enhance access to care.
• Veradius Unity Mobile C-Arm – Improves workflow and throughput by establishing exceptional communication between the physician, operator and C-arm.
• IntelliSpace Portal – Integrating data from multiple imaging systems to give clinicians a more comprehensive view of every patient.

Philips and its physician partners will be hosting a Lunch n’ Learn symposium on Wednesday, December 3rd at 12:30 p.m. to discuss photon counting technology for mammography, spectral breast density measurement, and spectral lesion characterization (South Hall, Room 403A), and participating in additional presentations throughout the meeting. Topics include techniques for interventional sonography and thermal ablation, interventional breast procedures, evaluation of coronary stents with coronary CT angiography, musculoskeletal ultrasound, and fast and robust MR-related vascular, cardiac, spine and brain imaging.

Philips will showcase its radiology solutions in booth #6742 at the Radiological Society of North America Annual Meeting (RSNA), November 30th through December 5th in Chicago, Ill. Visit www.philips.com/rsna or www.philips.com/healthcare and follow @PhilipsHealth for more information on Philips’ presence at #RSNA14.

* Affiniti received its CE Mark on September 9, 2014. Affiniti is available for sale in Europe and Asia, with the U.S. launch slated for 2015.

Philips and Netherlands Cancer Institute expand collaboration with new agreement to enable personalized cancer care and improve outcomes for cancer patients

• Collaboration will benefit patients through innovations that improve the hospital’s capabilities in integrated cancer diagnostics, image guided therapies and research
• Agreement gives the Netherlands Cancer Institute access to latest state-of-the-art medical imaging and healthcare informatics technologies

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) and the Netherlands Cancer Institute today announced a new agreement that expands their long-term collaboration and enforces the mission of the Netherlands Cancer Institute in offering the best possible care to cancer patients. The agreement will give the only Comprehensive Cancer Centre in the Netherlands access to the latest healthcare innovations to contribute to the institute’s spearheads: personalized medicine and image guided precision treatment.

The Netherlands Cancer Institute and Philips will be working closely together to realize a paradigm shift in the surgical treatment of cancer patients to improve their treatment outcomes. They aim to advance from ‘standard’ surgical procedures towards personalized precision surgery to enable improved first-time-right removal of all tumor tissue. To this end, the agreement includes an innovative hybrid suite, a combination of a sterile conventional operating room with a lab for image guided therapies. It offers an integrated and comprehensive solution in which a wide range of procedures can be performed from conventional surgery to new live 3D image guided therapies.

The Netherlands Cancer Institute also joins a group of early adopters with the commercial installation of the new Philips Vereos – the world’s first and only digital PET/CT system - that through its digital detector technology offers high image resolution at low radiation dose. It will support the Netherlands Cancer Institute enhancing cancer diagnosis and staging and advancing personalized medicine in oncology.

The new agreement expands the existing research collaboration between the organizations, which has been in place since 2011. Besides the development of image-guided surgery, the partners are also working together to optimize radiotherapy planning. The Netherlands Cancer Institute is also a member of a research consortium led by Elekta and supported by Philips as the MRI technology partner. The consortium is developing the world’s first high-field MR-guided radiation therapy system to allow doctors to adapt radiation therapy during the procedure. This could improve treatment accuracy, potentially reducing side effects and enabling increases in the therapeutic dose.

“As a Comprehensive Cancer Centre combining state-of-the-art research and hospital facilities, we are committed to contributing to innovations that change clinical practice in patient care and to continuously improving our efficiency and patient centeredness. The new equipment will be used for diagnosing and staging cancer in the initial stages as well as for cutting-edge image-guided treatment and therapy monitoring. The new imaging capabilities will be a cornerstone of our research into personalized and image-guided therapy, allowing treatment plans to be tailored to the patient at the earliest stage for improved patient outcomes,” said Wim van Harten, board member and Director Organization and Management at the Netherlands Cancer Institute.

“Our ambition to develop impactful innovations can only be achieved by working closely with world-leading clinical partners like the Netherlands Cancer Institute,” said Frans van Houten, CEO of Royal Philips. “The new agreement reinforces the strong relationship we already have. By bringing our latest imaging and clinical informatics innovations for cancer diagnosis and treatment to this partnership, we can help improve care for patients at the center, while our extended joint research programs will lay the foundation for tomorrow’s integrated cancer care.”

The agreement further includes Philips’ digital Ingenia 3T MRI system, digitalization of their existing 3T MRI system through Philips’ dStream upgrade program and EPIQ and CX50 ultrasound. Healthcare informatics will give the hospital an integrated oncology solution that combines patient data across relevant imaging modalities to support disease diagnosis, treatment decision and tracking over time.

The Netherlands Cancer Institute is located in Amsterdam. Its research institute accommodates approximately 750 scientists and scientific support personnel. Its hospital, Antoni van Leeuwenhoek, employs over 150 medical specialists and is continuously renovating its facilities. In 2015 it will include 220 beds, 10 operating rooms, 11 radiotherapy units and an outpatient clinic that sees over 8000 new cancer patients per year. It is the only OECI designated Comprehensive Cancer Centre in the Netherlands, and is an important national and international center of scientific and clinical expertise, development and training.